The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease
Nutrition, Metabolism and Cardiovascular Diseases · 2024-08 · 34 (8) · 1922-1931
DOI: 10.1016/j.numecd.2024.04.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2024-08. Verfasst von Yufeng Yin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, The First Affiliated Hospital of Soochow University, Jiangsu Suzhou 215006, China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Predictive Value of Tests, Nutrition Surveys. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: The systemic inflammation response index (SIRI) is associated with various diseases with inflammatory components, but its relationship with the progression of hepatic fibrosis and survival outcomes in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is still unclear. This study was designed to investigate the potential associations between the SIRI and advanced hepatic fibrosis (AHF) as well as between the SIRI and long-term outcomes in individuals with MASLD. METHODS AND RESULTS: A prospective cohort study was conducted using data gathered from the National Health and Nutrition Examination Survey (NHANES) spanning from 2005 to 2016. Weighted binary logistic regression, the Cox proportional hazards model, and time-dependent receiver operating characteristic (ROC) analyses were employed to assess the relationships among the SIRI, AHF, and mortality in patients with MASLD. Our study included a total of 5126 patients with MASLD. A higher SIRI was significantly associated with increased odds of AHF (OR 1.55, 95% CI 1.22, 1.96). According to the survival analyses, a higher SIRI was associated with greater all-cause (HR 1.19, 95% CI 1.15, 1.22) and cardiovascular mortality (HR 1.25, 95% CI 1.19, 1.32) after adjustment. The time-dependent ROC analysis indicated that the SIRI had a modest predictive value for discriminating MASLD individuals at higher versus lower mortality risk over 3-year, 5-year, and 10-year follow-up. CONCLUSIONS: The SIRI is a promising tool for identifying MASLD individuals at risk of progressing to AHF and for predicting mortality outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, The First Affiliated Hospital of Soochow University, Jiangsu Suzhou 215006, China.
- Department of Gastroenterology, Wuxi Xinwu District Xinrui Hospital, Jiangsu Wuxi 214000, China.
- Department of Gastroenterology, Wuxi Xinwu District Xinrui Hospital, Jiangsu Wuxi 214000, China. Electronic address: xuqingling0926@163.com.
Zitieren
APA
Yin, Y., Zhu, W., & Xu, Q. (2024). The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease. Nutrition, Metabolism and Cardiovascular Diseases, 34(8), 1922-1931. https://doi.org/10.1016/j.numecd.2024.04.018
Vancouver
Yin Y, Zhu W, Xu Q. The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease. Nutrition, Metabolism and Cardiovascular Diseases. 2024;34(8):1922-1931. doi:10.1016/j.numecd.2024.04.018
BibTeX
@article{Yin2024,
author = {Yin, Yufeng and Zhu, Weijia and Xu, Qingling},
title = {The systemic inflammation response index as a risk factor for hepatic fibrosis and long-term mortality among individuals with metabolic dysfunction-associated steatotic liver disease},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2024},
volume = {34},
number = {8},
pages = {1922--1931},
doi = {10.1016/j.numecd.2024.04.018}
}
EUVIMED